Retatrutide 20mg + Trizepatide 40mg (10ml) – 60mg (10 vials)

Product Overview

This listing describes a combination of retatrutide and tirzepatide. Both compounds are associated with research into metabolic signaling, but they have different pharmacological profiles and regulatory statuses. Retatrutide remains investigational, while tirzepatide is an authorized prescription medicine in certain jurisdictions and for specific indications.

Scientific Background

Retatrutide is being investigated for activity at GLP-1, GIP, and glucagon receptors. Tirzepatide acts on GIP and GLP-1 receptors. Their combined presence in a product should not be interpreted as evidence that the combination is safe, effective, or approved for any particular use.

Product Specifications

• Product Name: Retatrutide + Tirzepatide
• Listed Retatrutide Amount: 20mg
• Listed Tirzepatide Amount: 40mg
• Listed Combined Amount: 60mg
• Package Format: 10 vials
• Product Category: Peptide-based medicinal compounds

Product Information and Verification

Before publishing this listing, confirm the exact composition from the manufacturer’s label. Clarify whether the stated amounts are per vial or totals for the entire package, and verify what the “10ml” notation refers to. Confirm batch identification, storage requirements, product authorization, and available quality documentation. Do not advertise independent testing or purity levels without verifiable evidence.

Regulatory and Safety Disclaimer

Retatrutide is investigational, and tirzepatide is a regulated medicinal compound. The safety and effectiveness of this specific combination should not be assumed. Ensure the product is legally authorized for the intended market and that its listing complies with applicable medicine, advertising, and distribution regulations. This description is informational only and is not medical advice.